Other Events ·
Seres Therapeutics entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus…
MCRBSeres Therapeutics, Inc.
Seres Therapeutics entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC on July 31, 2026, to terminate its lease for approximately 21,295 square feet of space at 200 Sidney Street in Cambridge, Massachusetts. The agreement reduces annual facilities costs by surrendering the Early Termination Premises effective August 1, 2026, and shortens the remaining term for the Renewal Premises to December 31, 2026. Consideration includes increasing a letter of credit by approximately $2.2 million to a total of $3.6 million, paying a deferred termination fee of $3.85 million on or before January 4, 2027, and issuing 103,520 shares of common stock valued at approximately $0.5 million at $4.83 per share. Seres Therapeutics operates in the biotechnology industry, developing microbiome-based therapeutics.